Ying Zhu

A multi-stage prospective study evaluates serum metabolomic signatures for the differential diagnosis and prognostic stratification of PDAC

Background Pancreatic ductal adenocarcinoma (PDAC) lacks biomarkers for accurate diagnosis and prognostic stratification. The standard, CA19-9, has suboptimal specificity in differentiating PDAC from mimics like chronic pancreatitis (CP). We investigated serum metabolomic signatu...